Anagen formulation · 4 activesBGrowth Maxi without the lightest-evidence active

Budget Growth Maxi

Growth Maxi minus latanoprost. The four-active formulation keeps the strongest-evidence components (fin + min + T3 + levocetirizine) and drops the active with the smallest standalone RCT.

What's in it

Every active in Budget Growth Maxi

Each active in this formulation, scored against its own standalone evidence for AGA. Click any active for the full claim-by-claim breakdown.

Active	Grade	Why it's in this formula
Finasteride0.1%→DHT suppression	A	Topical 0.1% finasteride — same dose as Growth Maxi and The Basics.
Minoxidil5%→Follicular activator	A	Standard topical 5% minoxidil.
Liothyronine (T3)6.5 ng/mL→Anagen induction	C	Microdosed T3 for follicular activation via thyroid hormone receptor pathway.
Levocetirizine0.5%→Anti-inflammatory / anti-PGD2	C	Anti-PGD2 mechanism with supporting human RCT data (Zaky 2021).

The case for this stack

Why we paired these actives

Why drop latanoprost from the maximum stack

Budget Growth Maxi is the deliberate four-active version of Growth Maxi. The single component removed is latanoprost — and the editorial honest reason is straightforward: latanoprost has the lightest standalone RCT evidence in the original stack. The published latanoprost evidence for scalp AGA is essentially the Blume-Peytavi 2012 pilot RCT — n=16, 24 weeks. Positive direction of effect, but pilot-scale. Removing it cuts the formulation cost without removing any of the actives that carry larger evidence bases (fin and min are Grade A; T3 and levocetirizine each have their own supporting human data). The foundation — finasteride + minoxidil — remains the most-replicated combination protocol in AGA, backed by the 2025 meta-analysis of 7 RCTs (MD +9.22 hairs/cm² over minoxidil alone, p=0.04). T3 and levocetirizine layer additional mechanisms with independent human support. For users who want maximalist coverage without paying for the active with the smallest evidence base, this is the calibration point.

Cited literature

Li Y, Huang Q, Zhou Z, Zhang Y (2025). Comparing minoxidil-finasteride mixed solution with minoxidil solution alone for male androgenetic alopecia: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Medicine PMID 41127390
Blume-Peytavi U, et al. (2012). A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1%. J Am Acad Dermatol
Zaky MS, et al. (2021). Therapeutic implications of topical cetirizine 1% in treatment of male androgenetic alopecia. J Cosmet Dermatol PMID 33417284

What's been studied

The studies behind the combination

Like Growth Maxi, the four-active formulation itself has not been studied in an RCT — the evidence is per-component and per-pairing. Here are the studies most directly relevant.

Li 2025 — Topical fin + min meta-analysis

Frontiers in Medicine · PMID 41127390

What the science doesn't yet answer

No RCT of this exact four-active formulation. Same limitation as Growth Maxi minus the latanoprost question.
Whether the marginal benefit of latanoprost (the dropped component) is clinically meaningful in the context of a fin+min foundation is not directly studied.
Long-term outcomes of four-active topicals vs simpler two-active protocols (The Basics) are not characterized.

Bottom line

Our verdict on Budget Growth Maxi

Sensible price-tier of the maximum stack

Budget Growth Maxi is Growth Maxi minus the active with the smallest standalone evidence. The four remaining actives each have published human data; the foundation pairing (fin + min) carries Grade A meta-analytic support. For users who want maximalist mechanism coverage but at a lower price point — and who are comfortable trading off the lightest-evidence component — this is the rational choice. Same Grade B verdict as Growth Maxi because the four-active formulation is still not directly studied at these concentrations.

Same evidentiary footing as Growth Maxi without paying for the active that has the smallest standalone RCT. Drops the question mark, keeps the foundation.

Go deeper

Long-form analysis and primary-source breakdowns that go beyond the summary above.

Compare

How does Budget Growth Maxi compare to its closest Anagen siblings?

Growth MaxiB

Strong pairwise evidence, novel combination

Read the evidence →

The BasicsA

The cleanest evidence in the catalog

Read the evidence →

Mr. MiddlegroundB

Designed for the systemic-side-effect-averse

Read the evidence →

← Back to all treatments & brands

Anagen formulation · 4 activesBGrowth Maxi without the lightest-evidence active

Budget Growth Maxi

Growth Maxi minus latanoprost. The four-active formulation keeps the strongest-evidence components (fin + min + T3 + levocetirizine) and drops the active with the smallest standalone RCT.

What's in it

Every active in Budget Growth Maxi

Each active in this formulation, scored against its own standalone evidence for AGA. Click any active for the full claim-by-claim breakdown.

Active	Grade	Why it's in this formula
Finasteride0.1%→DHT suppression	A	Topical 0.1% finasteride — same dose as Growth Maxi and The Basics.
Minoxidil5%→Follicular activator	A	Standard topical 5% minoxidil.
Liothyronine (T3)6.5 ng/mL→Anagen induction	C	Microdosed T3 for follicular activation via thyroid hormone receptor pathway.
Levocetirizine0.5%→Anti-inflammatory / anti-PGD2	C	Anti-PGD2 mechanism with supporting human RCT data (Zaky 2021).

The case for this stack

Why we paired these actives

Why drop latanoprost from the maximum stack

Cited literature

Li Y, Huang Q, Zhou Z, Zhang Y (2025). Comparing minoxidil-finasteride mixed solution with minoxidil solution alone for male androgenetic alopecia: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Medicine PMID 41127390
Blume-Peytavi U, et al. (2012). A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1%. J Am Acad Dermatol
Zaky MS, et al. (2021). Therapeutic implications of topical cetirizine 1% in treatment of male androgenetic alopecia. J Cosmet Dermatol PMID 33417284

What's been studied

The studies behind the combination

Like Growth Maxi, the four-active formulation itself has not been studied in an RCT — the evidence is per-component and per-pairing. Here are the studies most directly relevant.

Li 2025 — Topical fin + min meta-analysis

Frontiers in Medicine · PMID 41127390

What the science doesn't yet answer

No RCT of this exact four-active formulation. Same limitation as Growth Maxi minus the latanoprost question.
Whether the marginal benefit of latanoprost (the dropped component) is clinically meaningful in the context of a fin+min foundation is not directly studied.
Long-term outcomes of four-active topicals vs simpler two-active protocols (The Basics) are not characterized.

Bottom line

Our verdict on Budget Growth Maxi

Sensible price-tier of the maximum stack

Same evidentiary footing as Growth Maxi without paying for the active that has the smallest standalone RCT. Drops the question mark, keeps the foundation.

Go deeper

Long-form analysis and primary-source breakdowns that go beyond the summary above.

Compare

How does Budget Growth Maxi compare to its closest Anagen siblings?

Growth MaxiB

Strong pairwise evidence, novel combination

Read the evidence →

The BasicsA

The cleanest evidence in the catalog

Read the evidence →

Mr. MiddlegroundB

Designed for the systemic-side-effect-averse